Patient’s demographic details, primary and secondary end points in the Part II study
| Control group (n = 16) | Study group (n = 16) | |
|---|---|---|
| Gender (male/female) | 10/6 | 11/5 |
| Age (yr) | 37.7 ± 10.3 | 39.3 ± 12.9 |
| CYP3A5 genotype | ||
| CYP3A5*1/*1 | 2 | 4 |
| CYP3A5*1/*3 | 14 | 12 |
| Initial tacrolimus single dose (mg/kg) | 0.064 ± 0.006 | 0.050 ± 0.002** |
| C0 of tacrolimus after initial dose (ng/ml) | 4.29 ± 1.42 | 7.31 ± 2.27** |
| Percent of out-of-range C0 after initial dose | 68.6% | 12.5%** |
| Number of dose adjustment to reach therapeutic range | 1.33 ± 0.78 | 0.17 ± 0.39** |
| Dose needed to achieve therapeutic range (mg/kg) | 0.080 ± 0.012 | 0.050 ± 0.006** |
| Acute rejection rates within 2 wk after transplantation | 6.25% | 6.25% |
| Serum creatinine on day 14 after transplantation (μmol/l) | 118.4 ± 29.1 | 124.3 ± 30.5 |
C0, trough concentration.
↵** P < 0.01, compared with control group.